251 related articles for article (PubMed ID: 17823117)
1. Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
Yoon H; Laxmikanthan G; Lee J; Blaber SI; Rodriguez A; Kogot JM; Scarisbrick IA; Blaber M
J Biol Chem; 2007 Nov; 282(44):31852-64. PubMed ID: 17823117
[TBL] [Abstract][Full Text] [Related]
2. Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.
Yoon H; Blaber SI; Evans DM; Trim J; Juliano MA; Scarisbrick IA; Blaber M
Protein Sci; 2008 Nov; 17(11):1998-2007. PubMed ID: 18697857
[TBL] [Abstract][Full Text] [Related]
3. Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases.
Yoon H; Blaber SI; Li W; Scarisbrick IA; Blaber M
Biol Chem; 2013 Jan; 394(1):137-47. PubMed ID: 23241590
[TBL] [Abstract][Full Text] [Related]
4. A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15.
Yoon H; Blaber SI; Debela M; Goettig P; Scarisbrick IA; Blaber M
Biol Chem; 2009 Apr; 390(4):373-7. PubMed ID: 19090718
[TBL] [Abstract][Full Text] [Related]
5. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin.
Emami N; Diamandis EP
J Biol Chem; 2008 Feb; 283(6):3031-3041. PubMed ID: 18056261
[TBL] [Abstract][Full Text] [Related]
6. Functional roles of human kallikrein-related peptidases.
Sotiropoulou G; Pampalakis G; Diamandis EP
J Biol Chem; 2009 Nov; 284(48):32989-94. PubMed ID: 19819870
[TBL] [Abstract][Full Text] [Related]
7. Interdependence of kallikrein-related peptidases in proteolytic networks.
Beaufort N; Plaza K; Utzschneider D; Schwarz A; Burkhart JM; Creutzburg S; Debela M; Schmitt M; Ries C; Magdolen V
Biol Chem; 2010 May; 391(5):581-7. PubMed ID: 20302517
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
9. Activation and activity of glycosylated KLKs 3, 4 and 11.
Guo S; Briza P; Magdolen V; Brandstetter H; Goettig P
Biol Chem; 2018 Sep; 399(9):1009-1022. PubMed ID: 29975661
[TBL] [Abstract][Full Text] [Related]
10. Targeting the kallikrein-related peptidases for drug development.
Sotiropoulou G; Pampalakis G
Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
[TBL] [Abstract][Full Text] [Related]
11. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.
Debela M; Beaufort N; Magdolen V; Schechter NM; Craik CS; Schmitt M; Bode W; Goettig P
Biol Chem; 2008 Jun; 389(6):623-32. PubMed ID: 18627343
[TBL] [Abstract][Full Text] [Related]
12. Evolutionary history of tissue kallikreins.
Pavlopoulou A; Pampalakis G; Michalopoulos I; Sotiropoulou G
PLoS One; 2010 Nov; 5(11):e13781. PubMed ID: 21072173
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation.
Sotiropoulou G; Pampalakis G
Biol Chem; 2010 Apr; 391(4):321-31. PubMed ID: 20180637
[TBL] [Abstract][Full Text] [Related]
14. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.
Filippou PS; Karagiannis GS; Musrap N; Diamandis EP
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):277-91. PubMed ID: 26886390
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization and expression of five novel canine kallikrein-related peptidases in mammary cancer.
Angelopoulou K; Karagiannis GS
Mamm Genome; 2010 Oct; 21(9-10):516-24. PubMed ID: 20853168
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U
Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.
Pasic MD; Olkhov E; Bapat B; Yousef GM
Biol Chem; 2012 Apr; 393(5):319-30. PubMed ID: 22505515
[TBL] [Abstract][Full Text] [Related]
18. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.
Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW
J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829
[TBL] [Abstract][Full Text] [Related]
19. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
20. Novel inhibitory activity for serine protease inhibitor Kazal type-3 (Spink3) on human recombinant kallikreins.
Assis DM; Zalazar L; Juliano MA; De Castro R; Cesari A
Protein Pept Lett; 2013 Oct; 20(10):1098-107. PubMed ID: 23590280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
